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Abstract
Introduction: Splenic angiosarcoma is a rare tumor with only a few cases reported in the literature. Surgical resection offers the best 
chance of cure for this aggressive neoplasm but is often precluded by infiltration of the tumor to surrounding critical structures. We 
report a case of a locally advanced angiosarcoma rendered operable by treatment with Paclitaxel monotherapy.
Case presentation: A 69 year old female presented with a high grade splenic angiosarcoma, considered inoperable due to the extent of 
local spread. She received three cycles of single agent Paclitaxel and underwent a successful resection of the tumor.
Conclusion: Chemotherapy options for splenic angiosarcoma are not well studied. Paclitaxel as monotherapy is a useful therapeutic 
option in down staging tumors, facilitating surgical resection and merits further study in clinical trials.
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Splenic angiosarcomas are exceedingly rare tumors 
with a very poor prognosis.1 Only a few cases have 
been  reported  in  the  literature,  since  its  original 
description by Langhans in 1879.2
Angiosarcomas have a highly variable histology 
and  can  be  mistaken  for  vascular  benign  tumors 
or  other  non  vascular  malignant  neoplasms.  On 
microscopy most of them have a well defined nodular 
homogenous appearance and all of them show a vaso-
formative component. Most of the tumors express at 
least one immunohistochemical marker of histiocytic 
differentiation (CD68 and/or lysozyme) and two or 
more  markers  of  vascular  differentiation  (CD  34, 
CD31, FVIII R Ag, VEGFR3).3
On  radiological  imaging,  these  tumors  show  an 
enlarged  spleen  (.12  cm),  usually  with  either  a 
solitary complex mass or multiple diffusely infiltrative 
heterogeneous masses.4 Metastases are a frequent find-
ing at the time of diagnosis with up to 70% of metastatic 
deposits involving the liver. Common sites of metastatic 
disease include lung followed by bone and liver.5 Low 
platelet counts are seen in 33% of splenic angiosarcoma 
cases, which should be considered in the differential 
diagnosis of unexplained thrombocytopenia.6
In a retrospective study of 82 angiosarcoma patients, 
those with a primary resectable tumor had a 5 year 
disease specific survival (DSS) rate of 60%. Sixty seven 
percent of these patients received adjuvant radiation and 
27% received chemotherapy. Tumors with intermediate 
or high grade pathology (76%) and those arising from 
previously  irradiated  or  lymphedematous  areas  had 
worse disease specific survival.7 In another study look-
ing at patients with advanced angiosarcomas, median 
disease-specific survival (DSS) for patients with locally 
recurrent disease and metastatic disease was 50 months 
(95% confidence interval (CI): 25.7–73.5 months) and 
10 months (95% CI: 7.9–12 months) respectively.8 Most 
of these studies included patients with angiosarcomas 
arising from various sites including soft tissues, breast, 
skin, viscera and bone. Due to a paucity of data, it 
is however unclear if splenic angiosarcomas have a 
different natural course of progression than sarcomas 
arising from other organs.
Several  chemotherapy  treatment  options  have 
been tried in patients with locally recurrent/metastatic 
angiosarcoma,  including  Paclitaxel  ±  Gemcitabine, 
Doxorubicin ± Ifosfamide, Docetaxel ± Gemcitabine,9 
Interferon alfa, Dacarbazine, Bevacizumab, Etoposide, 
Cisplatin and various combinations of these agents.10
Paclitaxel  is  an  alkaloid  ester  extracted  from 
the bark of the pacific yew tree (Taxus brevifolia) 
and  the  European  Yew  tree  (Taxus  baccata).11  It 
stabilizes the microtubules by inhibiting the process 
of  tubular  depolymerization.12  This  process  occurs 
during  the  metaphase/anaphase  transition  of  the 
mitotic cell cycle, resulting in an arrest of cell divi-
sion.13  It  also  demonstrates  antiangiogenic  activity 
by  inhibiting  endothelial  cell  proliferation,  motil-
ity and invasiveness, both in vivo and in vitro.14 In a 
phase II study of paclitaxel therapy in advanced soft 
tissue sarcoma,15 a complete response was seen in a 
patient with angiosarcoma of the scalp. A retrospec-
tive study of patients with angiosarcoma of the scalp 
has shown that Paclitaxel is effective in the treatment 
of angiosarcoma of the scalp16 with a major response 
(complete response + partial response) seen in 8 out 
of 9 (89%) patients. The median duration of response 
was  5  months. A  further  phase  II  clinical  trial  of 
paclitaxel in advanced angiosarcoma suggested that 
weekly paclitaxel is well tolerated and is associated 
with a progression free survival rates of 74% and 
45% at 2 months and 4 months respectively.17 At a 
median follow up of 8 months the study reported a 
progression free survival of 4 months and a median 
overall survival of 8 months.
Here we present a patient with locally advanced 
splenic angiosarcoma treated with single agent with 
neo-adjuvant Paclitaxel. Based on an extensive search 
of the available literature, we believe this is the first 
report of Paclitaxel facilitating surgical resection in 
locally advanced splenic angiosarcoma.
case presentation
A 69 year old Caucasian female presented to us with 
a 4 month history of pain in the left upper quadrant 
of the abdomen, associated with a 30 lb weight loss 
and progressive shortness of breath. A CT scan of the 
chest, abdomen and pelvis revealed an enlarged spleen 
containing multiple heterogeneous hypodense masses, 
extending through the capsule into the peritoneal cav-
ity, left anterolateral abdominal wall, left retrocrural 
space, and invading the left hemidiaphragm with the 
presence of at least 2 soft tissue implants superior to 
the left hemidiaphragm. A moderate sized left pleural 
effusion was also noted. An MRI scan of the brain 
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disease but no metastatic disease was identified.
A biopsy of this mass confirmed it to be a high 
grade angiosarcoma. She was assessed for surgery, but 
the tumor was considered too extensive for a surgical 
resection. She was then offered chemotherapy for down 
staging the tumor, and though there was no precedence 
for its usage in splenic angiosarcomas, Paclitaxel was 
chosen  in  view  of  its  established  efficacy  in  other 
locally  advanced,  unresectable  soft  tissue  sarcomas. 
She received a total of three cycles of Paclitaxel at a 
dose of 175 mg/m2 every three weeks, the most fre-
quently used dose schedule in a retrospective review of 
nine patients with angiosarcoma of the face and scalp.16 
She experienced grade 2 tiredness and neutropenia but 
otherwise remained free of systemic toxicity.
A  repeat  CT  of  the  chest  abdomen  and  pelvis 
after the third cycle of chemotherapy showed a 33% 
decrease in the tumor size, indicating a partial response 
as  per  RECIST  criteria.18  There  was  also  a  com-
plete resolution of her left hemidiaphragmatic tumor 
implants along with the left sided pleural effusion.
A splenectomy was then performed along with a 
resection of the left hemidiaphragm followed by a graft 
repair  of  the  diaphragm.  Pathological  examination 
of the resected specimen showed areas of extensive 
necrosis and also confirmed that her splenic angiosar-
coma  was  completely  resected,  with  clear  margins 
(Figs. 1 and 2). Also, no tumor extension was seen in 12 
regional lymph nodes that were resected during surgery. 
She was discharged home after a short, uneventful post-
operative stay in the surgical intensive care unit.
Following a four week break to allow recuperation 
from surgery, she was restarted on paclitaxel and has 
received a further three cycles of adjuvant therapy 
without  any  significant  toxicity.  She  continues  to 
remain  well  at  the  time  of  this  report,  14  months 
following the initiation of her chemotherapy.
Discussion
Splenic angiosarcoma is a rare tumor often presenting 
with  unresectable  disease.  The  propensity  of  the 
tumor  to  disseminate  locally  and  its  proximity  to 
critical  intra-abdominal  structures  often  precludes 
surgery at presentation. Chemotherapy is often used 
to  downstage  locally  advanced  angiosarcomas  to 
improve  respectability,  but  data  on  the  efficacy  of 
available therapeutic agents is limited. Treatment with 
Paclitaxel based regimes is shown to predict better 
DSS with a trend towards statistical significance (HR: 
0.67, P = 0.06).8 Paclitaxel had also been shown to 
achieve high rates of objective response in patients with 
Kaposi’s sarcoma, another vascular tumor, commonly 
seen in the immunocompromised individuals.19
Paclitaxel  is  a  generally  well  tolerated  drug 
and  can  be  used  even  in  patients  with  a  relatively 
modest performance status. The proximity of splenic 
angiosarcomas  to  the  kidneys  often  causes  ureteric 
obstruction  resulting  in  renal  impairment.  Renal 
clearance of Paclitaxel and its metabolites is minimal 
and accounts only for less than 10% of the excretion 
of  the  drug.20 Though  a  three  weekly  regime  is  the 
commonest  schedule  of  administration  of  this  drug, 
studies  attempting  to  increase  the  dose  intensity  by 
more frequent administration of the drug have shown 
such  regimes  to  be  well  tolerated,  simultaneously 
achieving good response rates.17,21 However, there are 
no comparative studies of the various dosing regimes to 
guide therapy at this stage, making it difficult to choose 
Figure 1. Gross resected specimen of splenic angiosarcoma showing 
extensive necrosis.
Figure 2. H7e stained section (40X) of splenic angiosarcoma.
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between the various available scheduling options. These 
factors would make Paclitaxel a strong choice for the 
management of splenic angiosarcomas.
conclusion
Our report shows that Paclitaxel can be administered 
safely  and  effectively  in  the  patients  with  locally 
advanced  splenic  angiosarcoma,  and  renders  the 
tumor highly resectable. Further randomized studies 
are  required  to  define  the  role  of  Paclitaxel  in 
comparison to other chemotherapeutic agents and also 
to determine its ideal dose schedule, in the treatment 
of visceral angiosarcomas.
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